SAN DIEGO, March 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT ® 4 study demonstrating remission of tardive ...
(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) Monday said it presented positive data from Phase 3 KINECT-HD study evaluating Ingrezza capsule in adults with Huntington's disease at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback